company background image
1167

Jacobio Pharmaceuticals GroupSEHK:1167 Stock Report

Market Cap

HK$14.4b

7D

-5.4%

1Y

n/a

Updated

25 Oct, 2021

Data

Company Financials +
1167 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

1167 Overview

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies.

Price History & Performance

Summary of all time highs, changes and price drops for Jacobio Pharmaceuticals Group
Historical stock prices
Current Share PriceHK$18.64
52 Week HighHK$13.00
52 Week LowHK$25.35
Beta0
1 Month Change-9.95%
3 Month Change0.65%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO29.27%

Recent News & Updates

Mar 21
What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Every investor in Jacobio Pharmaceuticals Group Co., Ltd. ( HKG:1167 ) should be aware of the most powerful shareholder...

Shareholder Returns

1167HK BiotechsHK Market
7D-5.4%0.9%2.1%
1Yn/a13.9%5.9%

Return vs Industry: Insufficient data to determine how 1167 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 1167 performed against the Hong Kong Market.

Price Volatility

Is 1167's price volatile compared to industry and market?
1167 volatility
1167 Beta0
Industry Beta0.98
Market Beta1

Stable Share Price: 1167 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 1167's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015213Yinxiang Wanghttps://www.jacobiopharma.com

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company’s lead drug development programs include two clinical-stage allosteric SHP2 inhibitors comprising JAB-3068 and JAB-3312 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also developing JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor to treat various RB1-deficient tumors; JAB-24000, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations.

Jacobio Pharmaceuticals Group Fundamentals Summary

How do Jacobio Pharmaceuticals Group's earnings and revenue compare to its market cap?
1167 fundamental statistics
Market CapCN¥11.81b
Earnings (TTM)-CN¥839.36m
Revenue (TTM)CN¥543.98m

21.7x

P/S Ratio

-14.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1167 income statement (TTM)
RevenueCN¥543.98m
Cost of RevenueCN¥97.25m
Gross ProfitCN¥446.73m
ExpensesCN¥1.29b
Earnings-CN¥839.36m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.09
Gross Margin82.12%
Net Profit Margin-154.30%
Debt/Equity Ratio0%

How did 1167 perform over the long term?

See historical performance and comparison

Valuation

Is Jacobio Pharmaceuticals Group undervalued compared to its fair value and its price relative to the market?

6.59x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1167's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1167's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1167 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.

PE vs Market: 1167 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1167's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1167 is overvalued based on its PB Ratio (6.6x) compared to the HK Biotechs industry average (4x).


Future Growth

How is Jacobio Pharmaceuticals Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

78.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1167 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1167 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1167 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1167's revenue (35.8% per year) is forecast to grow faster than the Hong Kong market (12.5% per year).

High Growth Revenue: 1167's revenue (35.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1167's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Jacobio Pharmaceuticals Group performed over the past 5 years?

22.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 1167 is currently unprofitable.

Growing Profit Margin: 1167 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 1167's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 1167's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1167 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50%).


Return on Equity

High ROE: 1167 has a negative Return on Equity (-46.81%), as it is currently unprofitable.


Financial Health

How is Jacobio Pharmaceuticals Group's financial position?


Financial Position Analysis

Short Term Liabilities: 1167's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥74.8M).

Long Term Liabilities: 1167's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥4.8M).


Debt to Equity History and Analysis

Debt Level: 1167 is debt free.

Reducing Debt: 1167 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 1167 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 1167 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 89.8% per year.


Dividend

What is Jacobio Pharmaceuticals Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1167's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1167's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1167's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1167's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1167's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Yinxiang Wang (56 yo)

2.17yrs

Tenure

Dr. Yinxiang Wang serves as Consultant at Shining Capital. He is an Executive Chairman at Jacobio Pharmaceuticals Co. Ltd. since August 20, 2020.Dr. Wang has been Director at Jacobio Pharmaceuticals Co. L...


Leadership Team

Experienced Management: 1167's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: 1167's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: 1167 only recently listed within the past 12 months.


Top Shareholders

Company Information

Jacobio Pharmaceuticals Group Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Jacobio Pharmaceuticals Group Co., Ltd.
  • Ticker: 1167
  • Exchange: SEHK
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$14.380b
  • Shares outstanding: 771.46m
  • Website: https://www.jacobiopharma.com

Number of Employees


Location

  • Jacobio Pharmaceuticals Group Co., Ltd.
  • Building F2
  • No. 88 Kechuang 6th Street
  • Beijing
  • 101111
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 16:59
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.